T. Rowe Price Investment Management Inc. Increases Stock Holdings in Immunocore Holdings PLC Sponsored ADR $IMCR

Key Points

• T. Rowe Price Investment Management Inc. increased its stake in Immunocore Holdings PLC by 5.2%, acquiring an additional 351,610 shares, which now represents approximately 14.08% of the company valued at $209.2 million.
• Analysts have mixed ratings on Immunocore, with six analysts rating it a "Buy", while others have issued "Hold" and "Sell" ratings, indicating a consensus rating of "Moderate Buy" and an average price target of $58.00.
• Immunocore reported a revenue increase of 30% year-over-year for the last quarter, surpassing analyst expectations, with a reported revenue of $130.65 million.

T. Rowe Price Investment Management Inc. grew its holdings in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) by 5.2% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 7,051,818 shares of the company's stock after purchasing an additional 351,610 shares during the period. T. Rowe Price Investment Management Inc. owned approximately 14.08% of Immunocore worth $209,228,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. GF Fund Management CO. LTD. bought a new stake in shares of Immunocore during the 4th quarter valued at approximately $25,000. Oppenheimer Asset Management Inc. acquired a new position in shares of Immunocore during the first quarter worth $225,000. Tema Etfs LLC bought a new position in shares of Immunocore in the 4th quarter valued at $330,000. Virtus ETF Advisers LLC lifted its stake in shares of Immunocore by 39.0% in the 4th quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company's stock valued at $340,000 after acquiring an additional 3,238 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in Immunocore by 3,318.1% during the 1st quarter. GAMMA Investing LLC now owns 19,107 shares of the company's stock worth $5,670,000 after acquiring an additional 18,548 shares during the last quarter. Institutional investors and hedge funds own 84.50% of the company's stock.

Immunocore Trading Down 0.7%

Shares of Immunocore stock traded down $0.24 on Tuesday, reaching $32.35. 65,599 shares of the company's stock were exchanged, compared to its average volume of 335,410. The company has a market capitalization of $1.63 billion, a P/E ratio of -81.23 and a beta of 0.77. Immunocore Holdings PLC Sponsored ADR has a 52 week low of $23.15 and a 52 week high of $39.33. The company has a debt-to-equity ratio of 1.01, a quick ratio of 5.86 and a current ratio of 5.89. The firm's 50-day moving average is $33.29 and its two-hundred day moving average is $31.31.

Immunocore (NASDAQ:IMCR - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.01. The company had revenue of $130.65 million during the quarter, compared to analyst estimates of $122.96 million. Immunocore had a negative net margin of 5.70% and a negative return on equity of 5.40%. Immunocore's revenue for the quarter was up 30.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.23) EPS. Sell-side analysts predict that Immunocore Holdings PLC Sponsored ADR will post -0.94 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

IMCR has been the topic of several research reports. HC Wainwright restated a "buy" rating and set a $100.00 price target on shares of Immunocore in a report on Monday, June 2nd. Oppenheimer lifted their target price on shares of Immunocore from $85.00 to $86.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Wall Street Zen cut shares of Immunocore from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Immunocore in a report on Tuesday, May 27th. They set a "buy" rating and a $65.00 price target on the stock. Finally, Jefferies Financial Group started coverage on Immunocore in a report on Monday. They issued a "buy" rating and a $48.00 price objective for the company. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Immunocore presently has a consensus rating of "Moderate Buy" and an average price target of $56.89.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.